Strategies to improve antimicrobial utilization with a special focus on developing countries
Antimicrobial resistance (AMR) is a high priority across countries as it increases morbidity,
mortality and costs. Concerns with AMR have resulted in multiple initiatives internationally …
mortality and costs. Concerns with AMR have resulted in multiple initiatives internationally …
Optimising antimicrobial use in humans–review of current evidence and an interdisciplinary consensus on key priorities for research
Addressing the silent pandemic of antimicrobial resistance (AMR) is a focus of the 2021 G7
meeting. A major driver of AMR and poor clinical outcomes is suboptimal antimicrobial use …
meeting. A major driver of AMR and poor clinical outcomes is suboptimal antimicrobial use …
Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data
Summary Background The WHO Access, Watch, and Reserve (AWaRe) antibiotic
classification framework aims to balance appropriate access to antibiotics and stewardship …
classification framework aims to balance appropriate access to antibiotics and stewardship …
Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): Results from a worldwide point …
I Pauwels, A Versporten, N Drapier… - Journal of …, 2021 - academic.oup.com
Abstract Objectives The WHO Access, Watch and Reserve (AWaRe) classification has been
developed to support countries and hospitals in promoting rational use of antibiotics while …
developed to support countries and hospitals in promoting rational use of antibiotics while …
Antibiotic prescribing patterns in Ghana, Uganda, Zambia and Tanzania hospitals: results from the global point prevalence survey (G-PPS) on antimicrobial use and …
Antimicrobial resistance (AMR) remains an important global public health issue with
antimicrobial misuse and overuse being one of the main drivers. The Global Point …
antimicrobial misuse and overuse being one of the main drivers. The Global Point …
A global point prevalence survey of antimicrobial use in neonatal intensive care units: the no-more-antibiotics and resistance (NO-MAS-R) study
P Prusakov, DA Goff, PS Wozniak, A Cassim… - …, 2021 - thelancet.com
Background Global assessment of antimicrobial agents prescribed to infants in the neonatal
intensive care unit (NICU) may inform antimicrobial stewardship efforts. Methods We …
intensive care unit (NICU) may inform antimicrobial stewardship efforts. Methods We …
Pseudomonas aeruginosa: a clinical and genomics update
AC Pelegrin, M Palmieri, C Mirande… - FEMS Microbiology …, 2021 - academic.oup.com
Antimicrobial resistance (AMR) has become a global medical priority that needs urgent
resolution. Pseudomonas aeruginosa is a versatile, adaptable bacterial species with …
resolution. Pseudomonas aeruginosa is a versatile, adaptable bacterial species with …
Neonatal Sepsis: The Impact of Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae
The convergence of a vulnerable population and a notorious pathogen is devastating, as
seen in the case of sepsis occurring during the first 28 days of life (neonatal period). Sepsis …
seen in the case of sepsis occurring during the first 28 days of life (neonatal period). Sepsis …
Variations in the consumption of antimicrobial medicines in the European Region, 2014–2018: findings and implications from ESAC-Net and WHO Europe
J Robertson, V Vlahović-Palčevski, K Iwamoto… - Frontiers in …, 2021 - frontiersin.org
Background: Surveillance of antimicrobial consumption (AMC) is important to address
inappropriate use. AMC data for countries in the European Union (EU) and European …
inappropriate use. AMC data for countries in the European Union (EU) and European …
Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an …
Background Sepsis is a major contributor to neonatal mortality, particularly in low-income
and middle-income countries (LMICs). WHO advocates ampicillin–gentamicin as first-line …
and middle-income countries (LMICs). WHO advocates ampicillin–gentamicin as first-line …